Bristol-Myers Squibb receives positive CHMP opinion in EU for Nivolumab
Bristol-Myers Squibb announced the Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion recommending that nivolumab, a PD-1 immune checkpoint inhibitor, be granted approval for the treatment of locally advanced or metastatic squamous non-small cell lung cancer. May 22, 2015